<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546323</url>
  </required_header>
  <id_info>
    <org_study_id>D3565C00003</org_study_id>
    <nct_id>NCT02546323</nct_id>
  </id_info>
  <brief_title>A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of of rosuvastatin 20 mg compared to
      placebo for treating Chinese patients with subclinical atherosclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, multicenter parallel group
      study assessing the effects of rosuvastatin 20 mg treatment for 104 weeks on the change in
      intimamedia thickness (IMT) of the common carotid artery (CCA), carotid bulb, and internal
      carotid artery (ICA) in adult Chinese subjects with subclinical atherosclerosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2015</start_date>
  <completion_date type="Actual">January 29, 2019</completion_date>
  <primary_completion_date type="Actual">January 29, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period</measure>
    <time_frame>From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).</time_frame>
    <description>CIMT measurements were made from ultrasound images of the common carotid artery (CCA), carotid bulb and internal carotid artery (ICA). The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. Twelve carotid artery sites were scanned at each visit and the 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for a specific segment. The annualized rate of change in the MeanMax CIMT measurements from each of the 12 sites, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left CCA</measure>
    <time_frame>From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).</time_frame>
    <description>CIMT measurements were made from ultrasound images of the near and far walls of the right and left CCA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left Carotid Bulb</measure>
    <time_frame>From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).</time_frame>
    <description>CIMT measurements were made from ultrasound images of the near and far walls of the right and left carotid bulb. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left ICA</measure>
    <time_frame>From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).</time_frame>
    <description>CIMT measurements were made from ultrasound images of the near and far walls of the right and left ICA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Rate of Change in the Mean of the Mean (MeanMean) CIMT of the Near and Far Walls of the Right and Left CCA</measure>
    <time_frame>From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).</time_frame>
    <description>CIMT measurements were made from ultrasound images of the near and far walls of the right and left CCA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the mean of the CIMT for this segment. The annualized rate of change in the MeanMean CIMT measurements, based on all scans performed during the study, was determined using a multi-level mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipid, Lipoprotein and Apolipoprotein Values at Final Visit: Last Observation Carried Forward (LOCF)</measure>
    <time_frame>From baseline (Week 0) to end-of-study (Week 104).</time_frame>
    <description>The percent change from baseline at final visit for lipid and lipoprotein measurements (low-density lipoprotein cholesterol [LDL-C], total cholesterol, high-density lipoprotein cholesterol [HDL-C], triglycerides, non-HDL-C, non-HDL-C/HDL-C ratio) and apolipoprotein measurements (apolipoprotein A-I [ApoA-I], apolipoprotein B [ApoB] and ApoB/ApoA-I ratio) was determined by analysis of covariance (ANCOVA) with treatment as a fixed effect and baseline value as a covariate. In the evaluation of change from baseline (Week 0) to the final visit at Week 104, any missing observations were imputed by LOCF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipid and Lipoprotein Values at Final Visit: Time Weighted Average</measure>
    <time_frame>From baseline (Week 0) to end-of-study (Week 104).</time_frame>
    <description>The percent change from baseline at final visit for lipid and lipoprotein measurements (LDL-C, total cholesterol, HDL-C, triglycerides, non-HDL-C, non-HDL-C/HDL-C ratio) was determined by ANCOVA with treatment as a fixed effect and baseline value as a covariate. In the evaluation of change from baseline (Week 0), the time-weighted average value was calculated as the value multiplied by the number of days since the last assessment, summed for all observations, and divided by the sum of days between all visits.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">543</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg tablets, Daily oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>20mg tablets, orally once daily for the duration of the 104-week treatment period</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study-specific procedures

          -  Male aged ≥45 and &lt;70 years or female aged ≥55 and &lt;70 years

          -  Subjects with only hypertension (as defined blood pressure ≥140/90 mmHg or on
             antihypertensive treatment) and age as CVD risk factors and subjects without
             hypertension who have 3 or more other risk factors (including age) must have &quot;Fasting
             LDL C of ≥120 mg/dL (3.1 mmol/L) and &lt;160 mg/dL (4.1mmol/L)&quot;; Subjects without
             hypertension who have fewer than 3 other risk factors (including age) must have
             &quot;Fasting LDL-C of ≥120 mg/dL (3.1 mmol/L) and &lt;190 mg/dL (4.9 mmol/L)&quot;

          -  Triglycerides &lt;500 mg/dL (5.65 mmol/L) at Visit 1

          -  HDL-C levels ≤60 mg/dL (1.6 mmol/L) at Visit 1

          -  Maximum IMT ≥1.2 mm and &lt;3.5 mm at any location in the carotid ultrasound scans
             conducted at both Visit 2 and Visit 3

          -  Willing to follow all study procedures including study visits, fasting blood draws,
             and compliance with study treatment regimen

        Exclusion Criteria:

          -  Use of pharmacologic lipid-lowering medications (eg, statins, fibrate derivatives,bile
             acid binding resins, niacin, or its analogues at doses &gt;400 mg or prescribed Chinese
             traditional drugs), including cholesterol-absorption inhibitors (CAIs), and CAI/statin
             combination, within 12 months prior to Visit 1

          -  Current or recent (within 2 weeks of Visit 1) use of supplements known to alter lipid
             metabolism (eg, soluble fibers [including &gt;2 teaspoons Metamucil® or
             psyllium-containing supplement per day] or other dietary fiber supplements, marine
             oils, sterol/stanol products, or other supplement determined at the discretion of the
             investigator)

          -  History of hypersensitivity reactions to other HMG-CoA reductase inhibitors

          -  Pregnant women, women who are breast-feeding, and women of childbearing potential who
             are not using chemical or mechanical contraception or who have a positive serum
             pregnancy test

          -  Clinical evidence of coronary artery disease (CAD) or any other atherosclerotic
             disease such as angina, MI, transient ischemic attack, symptomatic CAD,
             cerebrovascular accident, percutaneous coronary intervention, coronary artery bypass
             graft, peripheral arterial disease, abdominal aortic aneurysm

          -  History of cancer (other than basal cell carcinoma) in the past 2 years

          -  Uncontrolled hypertension defined as either a mean resting diastolic blood pressure of
             ≥110 mmHg or a resting systolic blood pressure of ≥180 mmHg recorded at any time
             during the screening period

          -  History of diabetes mellitus or current diabetes mellitus

          -  Uncontrolled hypothyroidism defined as a thyroid stimulating hormone (TSH) &gt;1.5 times
             the upper limit of normal (ULN) at Visit 1 or subjects whose thyroid replacement
             therapy was initiated within the last 3 months

          -  History of heterozygous or homozygous familial hypercholesterolemia or known
             hyperlipoproteinemia Types I, III, IV, or V (familial dysbetalipoproteinemia)

          -  Use of the disallowed concomitant medications within 12 months prior to Visit 1

          -  History of alcohol and/or drug abuse within the past 5 years

          -  Active liver disease or hepatic dysfunction as defined by elevations of ≥1.5 x ULN at
             Visit 1 in any of the following liver function tests: ALT, AST or bilirubin

          -  Serum creatine kinase (CK) &gt;3 x ULN at Visit 1

          -  Serum creatinine &gt;2.0 mg/dL (177 mmol/L) recorded during the screening period

          -  Participation in another investigational drug study, and having ingested
             investigational drug ≤4 weeks before enrollment in the screening period

          -  Previous randomization in the present study

          -  History of a significant medical or psychological condition that, in the opinion of
             the investigator, would compromise the subject's safety or successful participation in
             the study

          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff and/or staff at the study site)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongjun Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tian Tan Hospital, Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yundai Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100035</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bengbu</city>
        <zip>233060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chongqin</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haerbin</city>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ningbo</city>
        <zip>315010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200090</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300457</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wenzhou</city>
        <zip>CN-325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xian</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D3565C00003&amp;amp;attachmentIdentifier=d2d6e1c4-2f54-4e4f-a110-cba7a24b341c&amp;amp;fileName=D3565c00003_CSP_Redacted.pdf&amp;amp;versionIdentifier=</url>
    <description>redacted protocol</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D3565C00003&amp;amp;attachmentIdentifier=6d21d378-0561-421c-88fb-99dc030ad2e8&amp;amp;fileName=D3565c00003_SAP_Redacted.pdf&amp;amp;versionIdentifier=</url>
    <description>SAP_redacted</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <results_first_submitted>November 25, 2019</results_first_submitted>
  <results_first_submitted_qc>November 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2019</results_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rosuvastatin 20 mg treatment, Carotid Intima-Media Thickness, Chinese subjects, Subclinical atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02546323/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02546323/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Chinese patients with subclinical atherosclerosis and a 10-year ischemic cardiovascular disease (ICVD) risk of less than 10% (as assessed by the 2007 China Adult Dyslipidema Management Guidelines) were enrolled at 25 sites in China between 17 September 2015 and 29 January 2019.</recruitment_details>
      <pre_assignment_details>Eligible patients with carotid intima-media thickness (CIMT) measurements of maximum CIMT ≥1.2 millimeters (mm) and &lt;3.5 mm were randomized to receive either rosuvastatin 20 milligrams (mg) or corresponding placebo once daily. Randomization was stratified by ICVD risk (&lt;5% or 5% to 10%).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rosuvastatin 20 mg</title>
          <description>Rosuvastatin 20 mg was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="271"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="268"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="205"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility Criteria not Fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Specific Reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent-to-treat (ITT) analysis set consisted of all randomized patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Rosuvastatin 20 mg</title>
          <description>Rosuvastatin 20 mg was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="272"/>
            <count group_id="B2" value="271"/>
            <count group_id="B3" value="543"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.0" spread="5.23"/>
                    <measurement group_id="B2" value="59.7" spread="4.96"/>
                    <measurement group_id="B3" value="59.4" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="304"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="272"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>10-year ICVD Risk</title>
          <description>ICVD risk as collected by the Interactive Voice/Web Response System.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;5%</title>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="391"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥5% - &lt;10%</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period</title>
        <description>CIMT measurements were made from ultrasound images of the common carotid artery (CCA), carotid bulb and internal carotid artery (ICA). The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. Twelve carotid artery sites were scanned at each visit and the 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for a specific segment. The annualized rate of change in the MeanMax CIMT measurements from each of the 12 sites, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
        <time_frame>From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).</time_frame>
        <population>The ITT analysis set consisted of all randomized patients. Patients were analyzed according to the treatment to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period</title>
          <description>CIMT measurements were made from ultrasound images of the common carotid artery (CCA), carotid bulb and internal carotid artery (ICA). The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. Twelve carotid artery sites were scanned at each visit and the 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for a specific segment. The annualized rate of change in the MeanMax CIMT measurements from each of the 12 sites, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
          <population>The ITT analysis set consisted of all randomized patients. Patients were analyzed according to the treatment to which they were randomized.</population>
          <units>mm/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0038" spread="0.00312"/>
                    <measurement group_id="O2" value="0.0142" spread="0.00317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of annualized rate of change in MeanMax CIMT measurement difference between rosuvastatin 20 mg and placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <p_value_desc>Statistical significance of the MeanMax CIMT annualized rate of change between rosuvastatin 20 mg and placebo was evaluated using time-by-treatment interaction term in the model.</p_value_desc>
            <method>Multi-level mixed effects model</method>
            <param_type>Estimated mean difference</param_type>
            <param_value>-0.0103</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.00445</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0191</ci_lower_limit>
            <ci_upper_limit>-0.0016</ci_upper_limit>
            <estimate_desc>Randomized treatment group, time, time-by-treatment interaction, ICVD risk stratification, carotid artery site, center, age, sex, and scan reader were fixed effects. Random effects were the intercept and slope for individual patients.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left CCA</title>
        <description>CIMT measurements were made from ultrasound images of the near and far walls of the right and left CCA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
        <time_frame>From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).</time_frame>
        <population>The ITT analysis set consisted of all randomized patients. Patients were analyzed according to the treatment to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left CCA</title>
          <description>CIMT measurements were made from ultrasound images of the near and far walls of the right and left CCA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
          <population>The ITT analysis set consisted of all randomized patients. Patients were analyzed according to the treatment to which they were randomized.</population>
          <units>mm/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0031" spread="0.00310"/>
                    <measurement group_id="O2" value="0.0079" spread="0.00315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of annualized rate of change in MeanMax CIMT measurement difference between rosuvastatin 20 mg and placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>Statistical significance of the MeanMax CIMT annualized rate of change between rosuvastatin 20 mg and placebo was evaluated using time-by-treatment interaction term in the model.</p_value_desc>
            <method>Multi-level mixed effects model</method>
            <param_type>Estimated mean difference</param_type>
            <param_value>-0.0110</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.00442</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0197</ci_lower_limit>
            <ci_upper_limit>-0.0024</ci_upper_limit>
            <estimate_desc>Randomized treatment group, time, time-by-treatment interaction, ICVD risk stratification, carotid artery site, center, age, sex, and scan reader were fixed effects. Random effects were the intercept and slope for individual patients.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left Carotid Bulb</title>
        <description>CIMT measurements were made from ultrasound images of the near and far walls of the right and left carotid bulb. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
        <time_frame>From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).</time_frame>
        <population>The ITT analysis set consisted of all randomized patients. Patients were analyzed according to the treatment to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left Carotid Bulb</title>
          <description>CIMT measurements were made from ultrasound images of the near and far walls of the right and left carotid bulb. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
          <population>The ITT analysis set consisted of all randomized patients. Patients were analyzed according to the treatment to which they were randomized.</population>
          <units>mm/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0067" spread="0.00634"/>
                    <measurement group_id="O2" value="0.0228" spread="0.00643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of annualized rate of change in MeanMax CIMT measurement difference between rosuvastatin 20 mg and placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.073</p_value>
            <p_value_desc>Statistical significance of the MeanMax CIMT annualized rate of change between rosuvastatin 20 mg and placebo was evaluated using time-by-treatment interaction term in the model.</p_value_desc>
            <method>Multi-level mixed effects model</method>
            <param_type>Estimated mean difference</param_type>
            <param_value>-0.0162</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.00903</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0339</ci_lower_limit>
            <ci_upper_limit>0.0015</ci_upper_limit>
            <estimate_desc>Randomized treatment group, time, time-by-treatment interaction, ICVD risk stratification, carotid artery site, center, age, sex, and scan reader were fixed effects. Random effects were the intercept and slope for individual patients.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left ICA</title>
        <description>CIMT measurements were made from ultrasound images of the near and far walls of the right and left ICA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
        <time_frame>From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).</time_frame>
        <population>The ITT analysis set consisted of all randomized patients. Patients were analyzed according to the treatment to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left ICA</title>
          <description>CIMT measurements were made from ultrasound images of the near and far walls of the right and left ICA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
          <population>The ITT analysis set consisted of all randomized patients. Patients were analyzed according to the treatment to which they were randomized.</population>
          <units>mm/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0077" spread="0.00502"/>
                    <measurement group_id="O2" value="0.0120" spread="0.00511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of annualized rate of change in MeanMax CIMT measurement difference between rosuvastatin 20 mg and placebo.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.547</p_value>
            <p_value_desc>Statistical significance of the MeanMax CIMT annualized rate of change between rosuvastatin 20 mg and placebo was evaluated using time-by-treatment interaction term in the model.</p_value_desc>
            <method>Multi-level mixed effects model</method>
            <param_type>Estimated mean difference</param_type>
            <param_value>-0.0043</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.00716</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0183</ci_lower_limit>
            <ci_upper_limit>0.0097</ci_upper_limit>
            <estimate_desc>Randomized treatment group, time, time-by-treatment interaction, ICVD risk stratification, carotid artery site, center, age, sex, and scan reader were fixed effects. Random effects were the intercept and slope for individual patients.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Rate of Change in the Mean of the Mean (MeanMean) CIMT of the Near and Far Walls of the Right and Left CCA</title>
        <description>CIMT measurements were made from ultrasound images of the near and far walls of the right and left CCA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the mean of the CIMT for this segment. The annualized rate of change in the MeanMean CIMT measurements, based on all scans performed during the study, was determined using a multi-level mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
        <time_frame>From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).</time_frame>
        <population>The ITT analysis set consisted of all randomized patients. Patients were analyzed according to the treatment to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Rate of Change in the Mean of the Mean (MeanMean) CIMT of the Near and Far Walls of the Right and Left CCA</title>
          <description>CIMT measurements were made from ultrasound images of the near and far walls of the right and left CCA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the mean of the CIMT for this segment. The annualized rate of change in the MeanMean CIMT measurements, based on all scans performed during the study, was determined using a multi-level mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.</description>
          <population>The ITT analysis set consisted of all randomized patients. Patients were analyzed according to the treatment to which they were randomized.</population>
          <units>mm/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0011" spread="0.00191"/>
                    <measurement group_id="O2" value="0.0075" spread="0.00194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of annualized rate of change in MeanMean CIMT measurement difference between rosuvastatin 20 mg and placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Statistical significance of the MeanMean CIMT annualized rate of change between rosuvastatin 20 mg and placebo was evaluated using time-by-treatment interaction term in the model.</p_value_desc>
            <method>Multi-level mixed effects model</method>
            <param_type>Estimated mean difference</param_type>
            <param_value>-0.0086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.00272</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0139</ci_lower_limit>
            <ci_upper_limit>-0.0032</ci_upper_limit>
            <estimate_desc>Randomized treatment group, time, time-by-treatment interaction, ICVD risk stratification, carotid artery site, center, age, sex, and scan reader were fixed effects. Random effects were the intercept and slope for individual patients</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipid, Lipoprotein and Apolipoprotein Values at Final Visit: Last Observation Carried Forward (LOCF)</title>
        <description>The percent change from baseline at final visit for lipid and lipoprotein measurements (low-density lipoprotein cholesterol [LDL-C], total cholesterol, high-density lipoprotein cholesterol [HDL-C], triglycerides, non-HDL-C, non-HDL-C/HDL-C ratio) and apolipoprotein measurements (apolipoprotein A-I [ApoA-I], apolipoprotein B [ApoB] and ApoB/ApoA-I ratio) was determined by analysis of covariance (ANCOVA) with treatment as a fixed effect and baseline value as a covariate. In the evaluation of change from baseline (Week 0) to the final visit at Week 104, any missing observations were imputed by LOCF.</description>
        <time_frame>From baseline (Week 0) to end-of-study (Week 104).</time_frame>
        <population>The ITT analysis set consisted of all randomized patients. Patients were analyzed according to the treatment to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipid, Lipoprotein and Apolipoprotein Values at Final Visit: Last Observation Carried Forward (LOCF)</title>
          <description>The percent change from baseline at final visit for lipid and lipoprotein measurements (low-density lipoprotein cholesterol [LDL-C], total cholesterol, high-density lipoprotein cholesterol [HDL-C], triglycerides, non-HDL-C, non-HDL-C/HDL-C ratio) and apolipoprotein measurements (apolipoprotein A-I [ApoA-I], apolipoprotein B [ApoB] and ApoB/ApoA-I ratio) was determined by analysis of covariance (ANCOVA) with treatment as a fixed effect and baseline value as a covariate. In the evaluation of change from baseline (Week 0) to the final visit at Week 104, any missing observations were imputed by LOCF.</description>
          <population>The ITT analysis set consisted of all randomized patients. Patients were analyzed according to the treatment to which they were randomized.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.47" spread="1.700"/>
                    <measurement group_id="O2" value="8.99" spread="1.727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.56" spread="1.010"/>
                    <measurement group_id="O2" value="1.29" spread="1.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.47" spread="0.944"/>
                    <measurement group_id="O2" value="0.48" spread="0.959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.26" spread="2.575"/>
                    <measurement group_id="O2" value="12.38" spread="2.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.67" spread="1.344"/>
                    <measurement group_id="O2" value="1.82" spread="1.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C/HDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.52" spread="1.637"/>
                    <measurement group_id="O2" value="3.23" spread="1.663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.20" spread="1.307"/>
                    <measurement group_id="O2" value="1.91" spread="1.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="0.784"/>
                    <measurement group_id="O2" value="0.96" spread="0.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB/ApoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.14" spread="1.450"/>
                    <measurement group_id="O2" value="1.63" spread="1.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): LDL-C</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-35.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.426</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.23</ci_lower_limit>
            <ci_upper_limit>-30.70</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): total cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-21.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.441</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.68</ci_lower_limit>
            <ci_upper_limit>-19.02</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): HDL-C</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>5.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.347</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.35</ci_lower_limit>
            <ci_upper_limit>7.64</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): Triglycerides</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-19.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.671</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.86</ci_lower_limit>
            <ci_upper_limit>-12.44</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): Non-HDL-C</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-29.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.917</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.25</ci_lower_limit>
            <ci_upper_limit>-25.72</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): Non-HDL-C/HDL-C ratio</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-31.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.334</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.33</ci_lower_limit>
            <ci_upper_limit>-27.16</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): ApoB</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-26.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.840</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.73</ci_lower_limit>
            <ci_upper_limit>-22.50</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): ApoA-I</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>2.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.104</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>4.36</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): ApoB/ApoA-I ratio</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-26.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.78</ci_lower_limit>
            <ci_upper_limit>-22.76</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipid and Lipoprotein Values at Final Visit: Time Weighted Average</title>
        <description>The percent change from baseline at final visit for lipid and lipoprotein measurements (LDL-C, total cholesterol, HDL-C, triglycerides, non-HDL-C, non-HDL-C/HDL-C ratio) was determined by ANCOVA with treatment as a fixed effect and baseline value as a covariate. In the evaluation of change from baseline (Week 0), the time-weighted average value was calculated as the value multiplied by the number of days since the last assessment, summed for all observations, and divided by the sum of days between all visits.</description>
        <time_frame>From baseline (Week 0) to end-of-study (Week 104).</time_frame>
        <population>The ITT analysis set consisted of all randomized patients. Patients were analyzed according to the treatment to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 20 mg</title>
            <description>Rosuvastatin 20 mg was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipid and Lipoprotein Values at Final Visit: Time Weighted Average</title>
          <description>The percent change from baseline at final visit for lipid and lipoprotein measurements (LDL-C, total cholesterol, HDL-C, triglycerides, non-HDL-C, non-HDL-C/HDL-C ratio) was determined by ANCOVA with treatment as a fixed effect and baseline value as a covariate. In the evaluation of change from baseline (Week 0), the time-weighted average value was calculated as the value multiplied by the number of days since the last assessment, summed for all observations, and divided by the sum of days between all visits.</description>
          <population>The ITT analysis set consisted of all randomized patients. Patients were analyzed according to the treatment to which they were randomized.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.89" spread="1.275"/>
                    <measurement group_id="O2" value="4.62" spread="1.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.98" spread="0.798"/>
                    <measurement group_id="O2" value="1.49" spread="0.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.07" spread="0.737"/>
                    <measurement group_id="O2" value="3.41" spread="0.748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.05" spread="2.091"/>
                    <measurement group_id="O2" value="9.36" spread="2.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.59" spread="1.072"/>
                    <measurement group_id="O2" value="1.19" spread="1.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C/HDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.31" spread="1.288"/>
                    <measurement group_id="O2" value="-0.38" spread="1.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): LDL-C</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-39.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.819</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.08</ci_lower_limit>
            <ci_upper_limit>-35.94</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): total cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-25.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.139</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.70</ci_lower_limit>
            <ci_upper_limit>-23.23</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): HDL-C</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>3.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.051</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.60</ci_lower_limit>
            <ci_upper_limit>5.73</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): Triglycerides</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-18.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.981</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.26</ci_lower_limit>
            <ci_upper_limit>-12.55</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): Non-HDL-C</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-33.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.529</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.78</ci_lower_limit>
            <ci_upper_limit>-30.78</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference (rosuvastatin 20 mg - placebo): Non-HDL-C/HDL-C ratio</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-33.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.836</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.54</ci_lower_limit>
            <ci_upper_limit>-30.32</ci_upper_limit>
            <estimate_desc>Treatment as a fixed effect and baseline value as a covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment Emergent Adverse Events were collected from day of first dose in Week 0 up to and including 10 days following the date of last dose of investigational product or placebo (up to Week 104).</time_frame>
      <desc>The safety analysis set consisted of all patients who took at least 1 dose of investigational product or placebo. Patients were analyzed according to treatment actually received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rosuvastatin 20 mg</title>
          <description>Rosuvastatin 20 mg was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo was administered in oral tablet form, once daily, for a 104-week (2-year) treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pathologic myopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pterygium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Mycosis fungoides</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Salivary gland cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Henoch-Schonlein purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="39" subjects_affected="23" subjects_at_risk="272"/>
                <counts group_id="E2" events="23" subjects_affected="15" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="79" subjects_affected="52" subjects_at_risk="272"/>
                <counts group_id="E2" events="77" subjects_affected="56" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="74" subjects_affected="49" subjects_at_risk="272"/>
                <counts group_id="E2" events="71" subjects_affected="54" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="272"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="272"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="272"/>
                <counts group_id="E2" events="24" subjects_affected="16" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="272"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="272"/>
                <counts group_id="E2" events="27" subjects_affected="21" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Lead</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+1 302 885 1180</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

